Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 592 clinical trials
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC

diagnosed with advanced (stage IV) NSCLC, irrespective of PD-L1 status, and who have oligoprogressed to both immunotherapy with an anti PD-1 agent (e.g., pembrolizumab or nivolumab) and 1 line of

  • 0 views
  • 03 Mar, 2021
  • 1 location
Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors

TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1),which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity

  • 1 views
  • 23 Jan, 2021
  • 1 location
Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer

Cancer immunotherapy with immunostimulatory antibodies targeting the CTLA-4 or PD-1/PD-L1 pathways has demonstrated its efficacy in variable proportions of cancer. For metastatic colorectal

  • 0 views
  • 26 Jan, 2021
  • 2 locations
Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer

after concurrent CRT. Immunotherapy targeting the PD-1/PD-L1 checkpoints has demonstrated promising activity in advanced EC. The aim of this study was to evaluate the efficacy and safety of the

  • 2 views
  • 22 Jan, 2021
  • 1 location
Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions

is a possible key in malignant transformation. In this regard, the activation of the PD-1/PD-L1 pathway has a central role, witnessed by the expression of PD-L1 by multiple cell types within the

  • 0 views
  • 27 Jan, 2021
  • 5 locations
A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients

aggressive tumours and reduced survival and renal tumours that express PD-L1 are more aggressive with poorer outcome. Blocking this receptor/ligand interaction with monoclonal antibodies can restore the

  • 0 views
  • 26 Jan, 2021
  • 3 locations
Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer

efficacy of neoadjuvant therapy is an important clinical problem to be solved. Immunotherapy targeting the PD-1/PD-L1 checkpoints has demonstrated promising activity in advanced EC especially in

  • 0 views
  • 25 Jan, 2021
  • 1 location
Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)

This is a phase II clinical trial aimed at evaluating the efficacy of PD-L1 inhibition with atezolizumab in advanced squamous and non-squamous NSCLC patients previously treated with anti-PD-1

  • 22 views
  • 26 Jan, 2021
  • 2 locations
Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.

anti-PD-L1 Durvalumab immunotherapy in patients with Human Papilloma Virus (HPV)-related oropharyngeal squamous cell carcinoma. In this phase II trial, patients will be assigned in one of the

ct scan
carcinoma
measurable disease
neutrophil count
durvalumab
  • 1 views
  • 28 Jan, 2021
  • 3 locations
Safety Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

cell death 1 (PD-1), as well as effects on the immune system. 3) evaluate the utility of PD-L1 & additional exploratory markers as biomarkers that could aid in selection of appropriate subjects for

metastatic disease
systemic therapy
solid tumor
monoclonal antibodies
gastric cancer
  • 296 views
  • 25 Jan, 2021
  • 17 locations